Evidence map›Paper›PMID 34064687›Full record

ArticleCells2021

Berberine Improves Cognitive Impairment by Simultaneously Impacting Cerebral Blood Flow and β-Amyloid Accumulation in an APP/tau/PS1 Mouse Model of Alzheimer's Disease.

Chenghui Ye, Yubin Liang, Ying Chen, Yu Xiong, Yingfang She, Xiaochun Zhong, Hongda Chen, Min Huang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 2 pooled it
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 2 syntheses or guidelines pooled it, 52 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Chenghui YeDepartment of Neurology, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen 518107, China.
Yubin LiangDepartment of Neurology, Zhuhai People's Hospital (Zhuhai Hospital Affiliated with Jinan University), Zhuhai 519000, China.
Ying ChenDepartment of Neurology, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen 518107, China.
Yu XiongDepartment of Neurology, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen 518107, China.ORCID 0000-0001-5260-316X
Yingfang SheDepartment of Neurology, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen 518107, China.ORCID 0000-0002-2458-1896
Xiaochun ZhongDepartment of Neurology, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen 518107, China.
Hongda ChenDepartment of Traditional Chinese Medicine, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen 518107, China.
Min HuangDepartment of Neurology, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen 518107, China.
Sun Yat-sen University · CNJinan University · CN

Funding

National Natural Science Foundation of China 81901422Project of Traditional Chinese Medicine of Guangming District No.GM2019020029, No.GM2019020028Shenzhen Bureau of Science, Technology and Information JCYJ20180307151246821
6 · The paper itself

Abstract

Alzheimer's disease (AD) is accompanied by β-amyloid (Aβ), neurofibrillary tangles, and neuron cell death, and is one of the most commonly occurring diseases among the elderly. The pathology of AD is complex, involving Aβ overproduction and accumulation, tau hyperphosphorylation, and neuronal loss. In addition, chronic cerebral hypoperfusion (CCH) is ubiquitous in the AD patients and plans a pivotal role in triggering and exacerbating the pathophysiological progress of AD. The goal of this study was to investigate the neuroprotective properties of berberine (BBR) and the underlying mechanism. During the study, BBR was administrated to treat the triple-transgenic mouse model of Alzheimer's disease (3×Tg AD). To thoroughly evaluate the effects of the BBR administration, multiple manners were utilized, for instance, 3D arterial spin labeling technique, Morris water maze assay, immunofluorescence staining, TUNEL assay, laser speckle contrast imaging, western blotting, etc. The results showed that BBR ameliorated cognitive deficits in 3×Tg AD mice, reduced the Aβ accumulation, inhibited the apoptosis of neurons, promoted the formation of microvessels in the mouse brain by enhancing brain CD31, VEGF, N-cadherin, Ang-1. The new vessels promoted by BBR were observed to have a complete structure and perfect function, which in turn promoted the recovery of cerebral blood flow (CBF). In general, berberine is effective to 3×Tg AD mice, has a neuroprotective effect, and is a candidate drug for the multi-target prevention and treatment of AD.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesAnimalsApoptosisBerberineBrainCerebrovascular CirculationCognitive DysfunctionDisease Models, AnimalLearningMaleMaze LearningMemoryMiceMice, TransgenicMicrocirculationAmyloid beta-PeptidesBerberinePresenilin-1presenilin 1, mousetau ProteinsAlzheimer’s diseaseBBRcerebral blood flowβ-amyloid

Identifiers

PMID34064687
PMCPMC8150323
OpenAlexW3162839253

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.